StageUnattributed | Alive
About Clairvoyant Therapeutics
Clairvoyant Therapeutics is a biotechnology company focused on short path clinical trial speed to market strategy for psilocybin psycho-assisted therapy. The company was founded in 2021 and is based in Vancouver Canada.
Clairvoyant Therapeutics's Product Videos
Compete with Clairvoyant Therapeutics?
Ensure that your company and products are accurately represented on our platform.
Clairvoyant Therapeutics's Products & Differentiators
25 mg Psilocybin Capsule along with Psilocybin Therapy
Expert Collections containing Clairvoyant Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Clairvoyant Therapeutics is included in 1 Expert Collection, including Psychedelics.
Latest Clairvoyant Therapeutics News
Mar 20, 2023
Clinical Trial Exploring Psilocybin Therapy As A Treatment For Alcohol Use Disorder Achieves New Milestone March 20, 2023 8:09 AM | 2 min read Clairvoyant Therapeutics announced that the first clinical trial participant in Finland enrolled in CLA-PSY-201 has received their first dose of the drug along with motivational enhancement therapy. CLA-PSY-201 is the company's placebo-controlled, randomized, multi-site phase 2b trial exploring psilocybin therapy as a treatment for alcohol use disorder. The first CLA-PSY-201 trial site in Finland is overseen by principal investigator, Dr. Hannu Alho. Dr. Alho is a professor with the Finnish National Institute for Health and Welfare (THL) and chief doctor at Addiktum Oy, a Finnish company founded and owned by drug addiction treatment specialists and a research center for the study. This milestone means the trial is now underway on two continents. "We are excited to randomize our first patient in Europe," stated Damian Kettlewell, CEO and co-founder, Clairvoyant. "Likewise, the Clairvoyant team is pleased that six clinical trial sites are recruiting patients in Canada and Europe. An accelerating number of dosing visits are scheduled in March and subsequent months. We look forward to opening eight additional sites in the coming quarter to expedite patient recruitment and have a clear line of sight on an interim data readout in Q3 2023 and full recruitment by Q4 2023. We appreciate the ongoing support of our experienced and well-resourced clinical, regulatory and financial team and partners." Clairvoyant aims to be the first company to secure market authorization for psilocybin as a therapeutic product in Europe, the UK and Canada. The company remains on track to publish an interim data readout later this year. Benzinga's Cannabis Capital Conference Is Back The most successful cannabis business event in the world, the Benzinga Cannabis Capital Conference , returns to Miami for its 16th edition. This is the place where DEALS GET DONE, where money is raised, M&A starts, and companies meet investors and key partners. Join us at the Fontainebleau Miami Beach Hotel in Florida on April 11-12. Don’t miss out. Secure your tickets now . Prices will surge very soon. Photo: Benzinga edit with photo by Pavel Danilyuk on pexels © 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Clairvoyant Therapeutics Frequently Asked Questions (FAQ)
When was Clairvoyant Therapeutics founded?
Clairvoyant Therapeutics was founded in 2021.
Where is Clairvoyant Therapeutics's headquarters?
Clairvoyant Therapeutics's headquarters is located at Vancouver.
What is Clairvoyant Therapeutics's latest funding round?
Clairvoyant Therapeutics's latest funding round is Unattributed.
How much did Clairvoyant Therapeutics raise?
Clairvoyant Therapeutics raised a total of $2.75M.
Who are the investors of Clairvoyant Therapeutics?
Investors of Clairvoyant Therapeutics include Origin Therapeutics, Ambria Capital, Iter Investments and Negev Capital.
Who are Clairvoyant Therapeutics's competitors?
Competitors of Clairvoyant Therapeutics include Compass Pathways.
What products does Clairvoyant Therapeutics offer?
Clairvoyant Therapeutics's products include Psilocybin Medicine.
Compare Clairvoyant Therapeutics to Competitors
Mindbloom provides a platform that helps licensed psychiatric clinicians to achieve better outcomes for their patients with lower costs and greater convenience. The company provides science-backed mental health research and provides health and well-being treatments specifically through ketamine therapy for depression and anxiety.
NUE Life Health is a telemedicine startup that develops a mental wellness solution employing treatments such as psychedelic-assisted therapies, combined with a graph database-driven app. NUE Life Health was founded in 2020 and is based in Miami Beach, Florida.
Tryp Therapeutics (CNSX: TRYP) is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. Its main development program PFN program is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The company was founded in 2019 and is based in San Diego, California.
Mindmed discovers, develops, and deploys psychedelic inspired medicines to improve health, promote wellness and alleviate suffering.
Compass Pathways (NASDAQ: CMPS) operates as a pharmaceutical company. It develops the active substance psilocybin for the treatment of patients with treatment-resistant depression. The company was founded in 2016 and is based in Altrincham, United Kingdom.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.